Trials / Completed
CompletedNCT00599638
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
A TWO WEEK DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A PREGABALIN/PF-00489791 COMBINATION VERSUS PREGABALIN ALONE IN PATIENTS WITH POST-HERPETIC NEURALGIA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin | 75mg bid titrating to 150mg bid on day 4 |
| DRUG | pregabalin/PF-00489791 | Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2008-04-09
- Primary completion
- 2008-12-16
- Completion
- 2008-12-23
- First posted
- 2008-01-24
- Last updated
- 2021-08-05
- Results posted
- 2021-08-05
Locations
39 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00599638. Inclusion in this directory is not an endorsement.